Q Bio Unveils New MRI Technology

Q Bio Inc. has launched Tensor Field Mapping (TFM), a new technology for magnetic resonance imaging (MRI) that provides previously unimaginable detailed insights into the human body. Unlike traditional MRIs that provide qualitative data prone to machine or clinical variations, TFM delivers quantitative, harmonized imaging data that can be immediately accessed by artificial intelligence (AI) to accelerate diagnostics.
 
“For decades, MRI technology has been invaluable in diagnosing a wide range of medical conditions, yet it has been limited by its qualitative nature and the variability of the data,” Q Bio Founder, CEO, and Chief Technology Officer Jeff Kaditz said. “With the introduction of Tensor Field Mapping, we are taking a quantum leap forward, making multi-parametric quantification of tissues reproducible across machines, which is key to AI in MRI and personalized medicine.”
 
TFM resulted from extensive research and development by Q Bio’s experts in medical imaging, physics, and computational science, and will make its debut in the company’s upcoming Mark I full body scanner. The technology provides quantifiable data lacking in traditional MRIs so that properties of tissues can be measured and benchmarked on an ongoing basis. This advancement is crucial for the accurate disease diagnosis and treatment by enabling consistent and reliable imaging data that can be shared, pooled and compared, regardless of machines and clinical settings.
 
“Quantified MRIs have been anticipated for over 25 years, TFM has been the breakthrough that has made them the reality,” stated Q Bio Vice President of Imaging Thomas Witzel, who spearheaded the development. “By modeling the entire imaging process without idealizing assumptions about the hardware, we’re not only enhancing the quality of MRI data but also paving the way for the development of new MRI equipment optimized for speed and patient comfort.”
 
Key capabilities of TFM include:

• A 100-fold reduction in computational power requiring only a single GPU;
• Imaging harmonization across hardware, software and clinical variations for sharing and knowledge pooling;
• Maxwell regularization, which ensures accurate coil sensitivity modeling;
• Advanced field calibration and motion reconstruction techniques that enhance data accuracy and integrity. 

“Tensor Field Mapping is more than an innovative technology; it’s a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible,” Bio Q Chief Operating Officer Clarissa Shen added. “We look forward to sharing our collaborations with healthcare providers and researchers to bring the benefits of TFM to patients around the world.”
 
Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes. In addition to TFM’s upcoming debut in the Mark I full body scanner, the company also plans to explore the applicability of other hardware options. Founded in 2015 by Kaditz, Dr. Michael Snyder and Dr. Garry Choy, Q Bio’s technology provides a deeper understanding of the body and the ways in which it is changing. Q Bio’s platform is a quantitative, clinically-relevant assessment of personal human health. Investors include Andreessen Horowitz, Khosla Ventures, Founders Fund, Kaiser Foundation Hospitals and others.